DeepMed Research

ABBVIE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

Synagis® Liquid 50mg, 100mg for Intramuscular Injection Special Investigation in Immunocompromised Children With Synagis®

Completed

Conditions: Respiratory Syncytial Virus Infection

First Posted Date: 2013-12-20

Last Posted Date: 2017-03-20

Lead Sponsor: AbbVie

Target Recruit Count: 312

Registration Number: NCT02016690

Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Two Treatment Modules in Chinese Subjects With Moderate to Severe Crohn's Disease

Phase 2

Completed

Conditions: Crohn's Disease

Interventions: Biological: Adalimumab
Biological: Placebo for adalimumab

First Posted Date: 2013-12-19

Last Posted Date: 2018-05-30

Lead Sponsor: AbbVie

Target Recruit Count: 30

Registration Number: NCT02015793

A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors

Phase 1

Completed

Conditions: Colon Cancer
Gastric Cancer
Lung Cancer
Breast Cancer
Ovarian Cancer
Solid Tumors

Interventions: Drug: Placebo
Drug: Veliparib (ABT-888)

First Posted Date: 2013-12-12

Last Posted Date: 2017-11-20

Lead Sponsor: AbbVie

Target Recruit Count: 45

Registration Number: NCT02009631

Locations: 🇳🇱
Site Reference ID/Investigator# 117320, Groningn, Netherlands
🇺🇸
Site Reference ID/Investigator# 116015, Scottsdale, Arizona, United States
🇳🇱
Site Reference ID/Investigator# 117336, Maastricht, Netherlands

and more 2 locations

A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)

Phase 2

Completed

Conditions: Compensated Cirrhosis
Chronic Hepatitis C
Hepatitis C Virus

Interventions: Drug: ABT-530
Drug: ABT-493
Drug: ABT-450/r/ABT-267, ABT-333
Drug: Ribavirin (RBV)

First Posted Date: 2013-11-26

Last Posted Date: 2021-07-12

Lead Sponsor: AbbVie

Target Recruit Count: 89

Registration Number: NCT01995071

A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)

Phase 2

Completed

Conditions: Acute Myelogenous Leukemia
AML
Acute Myeloid Leukemia

Interventions: Drug: ABT-199

First Posted Date: 2013-11-26

Last Posted Date: 2018-06-06

Lead Sponsor: AbbVie

Target Recruit Count: 32

Registration Number: NCT01994837

A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199

Phase 1

Withdrawn

Conditions: Non-Hodgkin's Lymphoma

Interventions: Drug: ABT-199
Drug: Rifampin

First Posted Date: 2013-10-25

Last Posted Date: 2014-05-26

Lead Sponsor: AbbVie

Registration Number: NCT01969682

Locations: 🇺🇸
Site Reference ID/Investigator# 101416, Hackensack, New Jersey, United States

A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-199

Phase 1

Completed

Conditions: Non-Hodgkin's Lymphoma

Interventions: Drug: ABT-199
Drug: Ketoconazole

First Posted Date: 2013-10-25

Last Posted Date: 2017-11-20

Lead Sponsor: AbbVie

Target Recruit Count: 12

Registration Number: NCT01969669

Locations: 🇺🇸
Site Reference ID/Investigator# 97498, Tucson, Arizona, United States
🇺🇸
Site Reference ID/Investigator# 92593, Lebanon, New Hampshire, United States
🇺🇸
Site Reference ID/Investigator# 101415, Hackensack, New Jersey, United States

An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Non-Hodgkin's Lymphoma

Interventions: Drug: ABT-199

First Posted Date: 2013-10-25

Last Posted Date: 2019-12-19

Lead Sponsor: AbbVie

Target Recruit Count: 11

Registration Number: NCT01969695

Locations: 🇺🇸
University of Arizona Arthritis Center /ID# 101359, Tucson, Arizona, United States
🇺🇸
Dartmouth-Hitchcock Med Ctr /ID# 92596, Lebanon, New Hampshire, United States
🇺🇸
Hackensack Univ Med Ctr /ID# 101417, Hackensack, New Jersey, United States

Evaluation of Diet and Exercise in Prostate Cancer Patients

Completed

Conditions: Prostate Cancer

First Posted Date: 2013-10-11

Last Posted Date: 2022-08-09

Lead Sponsor: AbbVie

Target Recruit Count: 1331

Registration Number: NCT01960881

Locations: 🇨🇦
Exdeo Clinical Research Inc /ID# 116040, Abbotsford, British Columbia, Canada
🇨🇦
Dr. J. Paul Whelan, Inc. /ID# 120415, Victoria, British Columbia, Canada
🇨🇦
QE II Health Sciences Centre /ID# 118941, Halifax, Nova Scotia, Canada

and more 47 locations

Special Investigation in Patients With Intestinal Behcet's Disease (All Case Investigation)

Completed

Conditions: Behcet's Disease

First Posted Date: 2013-10-11

Last Posted Date: 2019-03-22

Lead Sponsor: AbbVie

Target Recruit Count: 473

Registration Number: NCT01960790

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy